INDV Indivior Pharmaceuticals, Inc.
Price Chart
Executive Summary
Indivior eliminated the Chief Scientific Officer position effective June 1, 2026, with Dr. Christian Heidbreder transitioning to an advisory role through year-end 2026 before termination without cause. The company also held its annual shareholder meeting, re-electing all eight director nominees and approving say-on-pay and auditor ratification with strong support. The CSO role elimination is a routine organizational change with no material financial impact disclosed.
Actionable Insight
Routine governance filing — no immediate trading catalyst. Monitor for any R&D pipeline implications from the CSO role elimination, though the transition suggests continuity through year-end 2026.
Key Facts
- Chief Scientific Officer position eliminated effective June 1, 2026
- Dr. Christian Heidbreder will serve in advisory capacity through December 31, 2026, then terminated without cause
- All eight director nominees re-elected at May 13, 2026 annual meeting
- Say-on-pay approved with 90,364,566 votes for vs 1,324,996 against
- Shareholders voted for annual say-on-pay frequency (91,848,954 votes for 1 year)
- PricewaterhouseCoopers ratified as auditor for FY2026 with 99,146,241 votes for
- 121,922,058 shares entitled to vote; 100,407,722 present at meeting
Financial Impact
No financial impact disclosed; CSO position elimination may yield modest cost savings but not quantified
Risk Factors
- CSO departure could signal reduced R&D prioritization or pipeline shift
- No successor named for CSO role — potential gap in scientific leadership
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001625297-26-000024 |
| Document: 0001625297-26-000024-index-headers.html | 0001625297-26-000024 |
| Document: 0001625297-26-000024-index.html | 0001625297-26-000024 |
| Document: 0001625297-26-000024.txt | 0001625297-26-000024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Insider Cluster
| $38.47 awaiting T+5 | awaiting T+5 | — | $38.48 (+0.03%) |
|
May 15, 2026
28d ago
|
8-K
| $36.54 $37.81 | ▲ +3.48% | ▲ +1.86% | $38.48 (+5.31%) |
|
May 4, 2026
5w ago
|
8-K
| $38.98 $38.84 | ▼ −0.36% | ▼ −3.30% | $38.48 (−1.28%) |
|
Apr 30, 2026
6w ago
|
8-K
| $36.78 $40.61 | ▲ +10.41% | ▲ +8.69% | $38.48 (+4.62%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $33.23 $36.78 | ▲ +10.68% | ▲ +9.77% | $38.48 (+15.80%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $32.31 $31.51 | ▼ −2.48% | ▼ −5.66% | $38.48 (+19.10%) |
|
Mar 13, 2026
13w ago
|
8-K
| $31.11 $29.30 | ▼ −5.82% | ▼ −3.70% | $38.48 (+23.69%) |
|
Mar 13, 2026
13w ago
|
Press Release
| $31.11 $29.30 | ▼ −5.82% | ▼ −3.70% | $38.48 (+23.69%) |
|
Mar 12, 2026
13w ago
|
8-K
| $30.86 $30.50 | ▼ −1.17% | ▼ −0.19% | $38.48 (+24.69%) |
|
Mar 6, 2026
14w ago
|
Insider Cluster
| $32.27 $31.11 | ▼ −3.59% | ▼ −2.07% | $38.48 (+19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access